Basic information |
Metabolite name | Acetic acid |
HMDB0000042 | |
C00033 | |
176 | |
Synonyms | Acetate |
No. of studies | 53 |
Relationship between Acetic acid and depression (count: 53) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Up |
Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Up |
Study M088 | Type3 | venlafaxine group vs. control group | Faece | Wistar rat | Down |
Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
Study M1002 | Type2 | high-fat diet + Faecalibaculum rodentium group vs. high-fat diet group | Faece | C57Bl6/J mouse | Up |
Study M1002 | Type2 | high-fat diet + Xiaoyao San group vs. high-fat diet group | Faece | C57Bl6/J mouse | Up |
Study M1003 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
Study M1003 | Type2 | CUMS + Morinda officinalis oligosaccharide group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M1003 | Type2 | CUMS + high dose of alcohol-soluble polysaccharides group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M1003 | Type2 | CUMS + low dose of alcohol-soluble polysaccharides group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M1006 | Type1 | maternal separation group vs. control group | Faece | C57BL/6J mouse | Down |
Study M1006 | Type2 | maternal separation + Bifidobacterium breve CCFM1025 group vs. maternal separation group | Faece | C57BL/6J mouse | Up |
Study M1009 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M1009 | Type2 | CUMS + multi-probiotics group vs. CUMS group | Faece | C57BL/6 mouse | Up |
Study M1016 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
Study M1016 | Type2 | CUMS + imipramine group vs. CUMS group | Faece | C57BL/6J mouse | Up |
Study M1016 | Type2 | CUMS + ginsenoside Rh4 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
Study M1017 | Type1 | post-stroke depression group vs. control group | Serum | C57BL/6j mouse | Up |
Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M1027 | Type1 | CUMS group vs. control group | Faece | Wistar rat | Up |
Study M1027 | Type2 | CUMS + low dose of berberine group vs. CUMS group | Faece | Wistar rat | Down |
Study M1027 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Wistar rat | Down |
Study M1027 | Type2 | CUMS + high dose of berberine group vs. CUMS group | Faece | Wistar rat | Down |
Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Down |
Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Brain | CD-1 mouse | Down |
Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Plasma | CD-1 mouse | Down |
Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Brain | CD-1 mouse | Up |
Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Liver | CD-1 mouse | Down |
Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Plasma | CD-1 mouse | Down |
Study M1048 | Type3 | adult probiotic group vs. adult control group | Brain | CD-1 mouse | Up |
Study M1048 | Type3 | adult probiotic group vs. adult control group | Plasma | CD-1 mouse | Down |
Study M1048 | Type3 | adult probiotic group vs. adult control group | Liver | CD-1 mouse | Down |
Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
Study M1066 | Type2 | CUMS + Shugan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
Study M1066 | Type2 | CUMS + Jianpi group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
Study M1086 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Down |
Study M1127 | Type2 | flavonoid-low orange cordial group, after 8-week treatment vs. baseline | Faece | Human | Up |
Study M1127 | Type2 | flavonoid-rich orange juice group, after 8-week treatment vs. baseline | Faece | Human | Up |
Study M1137 | Type2 | paclitaxel + sodium butyrate group vs. paclitaxel group | Faece | CD1 mouse | Up |
Study M1137 | Type3 | sodium butyrate group vs. control group | Faece | CD1 mouse | Up |
Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
Study M475 | Type1 | dHB group vs. HB group | Urine | Human | Up |
Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
Study M511 | Type1 | Susceptible group vs. control group | Hippocampus | Wistar/ST rat | Down |
Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
Study M589 | Type1 | current depression group vs. control group | Plasma | Human | Down |
Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
Study M665 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M667 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Down |
Study M667 | Type2 | CRS + crocin-I group vs. CRS group | Faece | C57BL/6 J mouse | Up |
Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
Study M706 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Up |
Study M707 | Type2 | CUMS + F45BB group vs. CUMS group | Faece | C57BL/6J mouse | Up |
Study M707 | Type2 | CUMS + S60 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
Study M708 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M778 | Type1 | LPS group vs. control group | Faece | C57BL/6J mouse | Down |
Study M778 | Type2 | LPS + NU9056 group vs. LPS group | Faece | C57BL/6J mouse | Up |
Study M804 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
Study M804 | Type2 | CUMS + high dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M804 | Type2 | CUMS + middle dose of WYJYD group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M845 | Type1 | CRS group vs. control group | Faece | Mouse | Down |
Study M872 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M872 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
Study M886 | Type1 | lead-exposed group vs. control group | Faece | Sprague-Dawley rat | Down |
Study M886 | Type2 | lead-exposed + probiotics group vs. lead-exposed group | Faece | Sprague-Dawley rat | Up |
Study M901 | Type1 | LPS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M901 | Type2 | LPS + Schisandrin group vs. LPS group | Faece | C57BL/6 mouse | Up |
Study M919 | Type1 | chronic cerebral hypoperfusion group vs. sham group | Hippocampus | Sprague-Dawley rat | Down |
Study M919 | Type1 | chronic cerebral hypoperfusion + FMT from chronic cerebral hypoperfusion group vs. sham operation + FMT from chronic cerebral hypoperfusion group | Hippocampus | Sprague-Dawley rat | Down |
Study M919 | Type2 | chronic cerebral hypoperfusion + FMT from sham group vs. chronic cerebral hypoperfusion + FMT from chronic cerebral hypoperfusion group | Hippocampus | Sprague-Dawley rat | Up |
Study M934 | Type2 | CUS + high-fat diet + 5-hydroxytryptophan group vs. CUS + high-fat diet group | Serum | C57BL/6J mouse | Up |
Study M967 | Type1 | bilateral common carotid artery occlusion group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Cecum | C57BL/6J mouse | Up |
Study M990 | Type1 | aged microbiota transplant group vs. young microbiota transplant group | Faece | C57BL/6 mouse | Down |